Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Antibiotics Market - Drivers, Trends, and Forecast | Technavio

Technavio Research
Posted on: 03 Oct 17

Technavio market research analysts forecast the global antibiotics market to grow at a CAGR of more than 2% during the forecast period, according to their latest report.

This Smart News Release features multimedia. View the full release here:

Technavio has published a new report on the global antibiotics market from 2017-2021. (Photo: Business Wire)

The market study covers the present scenario and growth prospects of the global antibiotics marketfor 2017-2021. The global antibiotics market is segmented into three regions based on geography which are APAC, the Americas, and EMEA. Among the regions, APAC dominated the market with the highest market share of more than 42% in 2016, followed by the Americas and EMEA. The high market share in APAC is due to the availability of increased patient pool and the rise in geriatric population.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

Technavio analysts highlight the following three market drivers that are contributing to the growth of the global antibiotics market:

  • Rising prevalence of infectious diseases
  • Growing awareness of the various diseases and its treatment
  • Special regulatory designations

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Rising prevalence of infectious diseases

Globally, there has been an increase in the number individuals affected by infectious diseases. Demographic changes caused by increased globalization and urbanization are a major factor leading to the global emergence of infectious diseases. Urbanization has led to the overcrowding of human inhabitation. High population densities in these areas favor colonization of disease pathogens and their persistence in human populations. An expansion of human cities has negatively affected our ecosystems and natural landscapes.

According to Sapna Jha, a lead analyst for infectious and rare diseases research at Technavio, “The growing number of dams, poor living conditions, lack of sanitation, and inadequate waste management systems are some of the other factors that have increased the incidence and prevalence of diseases. Also, changes in environmental conditions and the growing trade and travel are contributing to the increase in the occurrence of infectious diseases among people.”

Growing awareness of the various diseases and its treatment

The increased awareness of the various infections and their treatment options are leading to an increased use of drugs for the treatment of these diseases in the initial stages. This helps to prevent the aggravation of the disease and helps in the early-stage treatment. The awareness of these health issues can be increased by the presence of various programs. For instance, November 18, 2014, was celebrated as European Antibiotic Awareness Day to raise awareness of antibiotic resistance and promote judicious use of antibiotics. The HSS has developed "Healthy People 2020," which aims at the prevention and treatment of infectious diseases. Such awareness programs about the disease and the available treatment options increase the number of treatment-seeking population, thus driving the growth of the global antibiotics market.

Special regulatory designations

The increased rate of development of multidrug-resistant pathogens coupled with the limited number of drugs available for the treatment led to the development of GAIN Act by the US FDA. According to this act, any drug being developed for the treatment of "qualified infectious disease" will be granted a QIDP designation. This QIDP designation helps in the attainment of fast track designation and priority review for the drug. Thus, the drug will be developed at a faster rate and released into the market.

“The US FDA provides fast track designation to drugs used for treating serious diseases and addressing unmet medical needs. This designation includes benefits such as the eligibility for priority review for NDA if relevant criteria are met. This designation helps in the faster entry of the drugs into the market, thus boosting the market growth,” says Sapna.

Browse Related Reports:

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at

View source version on

Business Wire

Last updated on: 03/10/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.